- Trials with a EudraCT protocol (40)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
40 result(s) found for: DNA methylation analysis.
Displaying page 1 of 2.
| EudraCT Number: 2016-001407-23 | Sponsor Protocol Number: GEICAM/2015-06 | Start Date*: 2017-01-05 | |||||||||||
| Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama) | |||||||||||||
| Full Title: A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study). | |||||||||||||
| Medical condition: Patients with advanced triple negative breast cancer (TNBC) with BRCA1 and/or BRCA2 promoter methylation assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-000149-53 | Sponsor Protocol Number: D-STAPH | Start Date*: 2014-05-06 |
| Sponsor Name:Karolinska University Hospital, Huddinge | ||
| Full Title: ’D-STAPH’ Vitamin D supplementation to persistent carriers of MRSA – A double blind, randomised controlled trial | ||
| Medical condition: Persistent MRSA carriers | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-003977-24 | Sponsor Protocol Number: SGI-110-03 | Start Date*: 2014-03-20 | |||||||||||
| Sponsor Name:Astex Pharmaceuticals Inc | |||||||||||||
| Full Title: A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment with Sorafenib | |||||||||||||
| Medical condition: Advanced Hepatocellular Carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-023584-17 | Sponsor Protocol Number: RAS-AZIC | Start Date*: 2012-08-31 | |||||||||||
| Sponsor Name:Universität Leipzig | |||||||||||||
| Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent... | |||||||||||||
| Medical condition: acute myeloid leukeamia | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004418-17 | Sponsor Protocol Number: I-BCT-1 | Start Date*: 2014-05-07 |
| Sponsor Name:Oslo University Hospital | ||
| Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens. | ||
| Medical condition: breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NO (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-000586-19 | Sponsor Protocol Number: 307971 | Start Date*: 2005-07-25 |
| Sponsor Name:Bayer Schering Pharma AG | ||
| Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC) | ||
| Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2013-004444-31 | Sponsor Protocol Number: KWMP001 | Start Date*: 2015-01-09 |
| Sponsor Name: | ||
| Full Title: Effects and consequences for mother and child from treatment for depression A prospective randomized, placebo- controlled, trial with internet-based cognitive behavior therapy and sertraline or... | ||
| Medical condition: Prosepctive randomized two armed study to evaluate moderate depression during pregnancy treated with interbnetbased CBT and sertarline or placebo and longterm outcome in the children.Secondary obj... | ||
| Disease: | ||
| Population Age: Adults | Gender: Female | |
| Trial protocol: SE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-001563-12 | Sponsor Protocol Number: 20142017 | Start Date*: 2015-02-16 |
| Sponsor Name:University Medical Center Groningen | ||
| Full Title: Efficacy of Single inhaler Maintenance And Reliever Therapy (SMART) with Spiromax® budesonide/formoterol versus fixed dose treatment with Diskus® fluticasone/salmeterol in COPD | ||
| Medical condition: Chronic obstructive pulmonary disease (COPD) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2012-003689-41 | Sponsor Protocol Number: CRAD001YGB11 | Start Date*: 2012-11-19 |
| Sponsor Name:Novartis Pharmaceuticals UK Ltd | ||
| Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e... | ||
| Medical condition: oestrogen receptor positive breast cancer | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-002324-41 | Sponsor Protocol Number: PH2/051 | Start Date*: 2006-11-30 | |||||||||||
| Sponsor Name:Cancer Research UK | |||||||||||||
| Full Title: A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplat... | |||||||||||||
| Medical condition: Progressive, advanced ovarian cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-003003-31 | Sponsor Protocol Number: EORTC 26082 – 22081 | Start Date*: 2009-12-01 | |||||||||||
| Sponsor Name:EORTC Headquarters | |||||||||||||
| Full Title: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a ra... | |||||||||||||
| Medical condition: patients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoter | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-003335-29 | Sponsor Protocol Number: SIOPEATRT01 | Start Date*: 2021-04-15 |
| Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH | ||
| Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig... | ||
| Medical condition: atypical teratoid/rhabdoid tumours (ATRT) | ||
| Disease: | ||
| Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
| Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2015-001001-14 | Sponsor Protocol Number: IEO240 | Start Date*: 2015-10-07 | |||||||||||
| Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA | |||||||||||||
| Full Title: ¿A randomized placebo controlled phase II study with metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence (MetBreCS)¿ | |||||||||||||
| Medical condition: Metabolic-unbalanced breast cancer survivors at higher risk for recurrence (triple negative breast cancer, luminal B Her2 positive, non luminal HER2 positive) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-003530-13 | Sponsor Protocol Number: 18072011 | Start Date*: 2011-12-20 | |||||||||||
| Sponsor Name:Brighton & Sussex University Hospitals NHS Trust | |||||||||||||
| Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer | |||||||||||||
| Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-001447-40 | Sponsor Protocol Number: 28UCS2019 | Start Date*: 2020-06-29 | ||||||||||||||||
| Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA | ||||||||||||||||||
| Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer | ||||||||||||||||||
| Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-003701-15 | Sponsor Protocol Number: 20101228 | Start Date*: 2015-05-01 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis | |||||||||||||
| Medical condition: Axial Spondyloarthritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-004686-28 | Sponsor Protocol Number: 14143JK-AS | Start Date*: 2018-07-16 |
| Sponsor Name:Belfast Health and Social Care Trust (BHSCT) | ||
| Full Title: A randomised, double-blind, placebo-controlled trial to evaluate the effect of Epstein-Barr virus suppression in chronic obstructive pulmonary disease (EViSCO trial). | ||
| Medical condition: Epstein-Barr virus infection in patients with chronic obstructive pulmonary disease. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-004015-31 | Sponsor Protocol Number: WPD-201 | Start Date*: 2021-09-10 | |||||||||||
| Sponsor Name:WPD Pharmaceuticals Sp. z o.o. | |||||||||||||
| Full Title: A Multicenter, Open-Label Study of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients with Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failur... | |||||||||||||
| Medical condition: Glioblastoma Multiforme | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: PL (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003319-12 | Sponsor Protocol Number: ICR-CTSU-2014-10046 | Start Date*: 2015-03-27 | |||||||||||
| Sponsor Name:The Royal Marsden NHS Foundation Trust [...] | |||||||||||||
| Full Title: Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) | |||||||||||||
| Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2012-005350-39 | Sponsor Protocol Number: 20122011 | Start Date*: 2013-04-22 |
| Sponsor Name:University Medical Centre Groningen | ||
| Full Title: Effects Of extra-fine particle HFA-becLomethasone (HFA-QVAR) Versus course particle treatment In smokers and ex-smokers with Asthma | ||
| Medical condition: Asthma | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: NL (Ongoing) | ||
| Trial results: (No results available) | ||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.